Use of antiandrogens as therapy for women with polycystic ovary syndrome

Fertility and Sterility

Volumn 86, Issue SUPPL. 1, 2006, Pages

  Moghetti, Paolo ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Antiandrogens; flutamide; hyperandrogenism; polycystic ovary syndrome

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR BLOCKING AGENT; ANTIANDROGEN; ESTROGEN PROGESTAGEN; FLUTAMIDE; INSULIN SENSITIZING AGENT; STEROID 5ALPHA REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ANDROGEN BLOOD LEVEL; ARTICLE; BODY COMPOSITION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; FEMALE; HIRSUTISM; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; LIVER TOXICITY; METABOLISM; OVARY POLYCYSTIC DISEASE; OVULATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR BINDING;

ADULT; ANDROGEN ANTAGONISTS; FEMALE; FLUTAMIDE; HUMANS; HYPERANDROGENISM; POLYCYSTIC OVARY SYNDROME;

EID: 33745206131     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2006.04.014     Document Type: Article

References (8)

1. Moghetti P. Insulin resistance. what is its role in PCOS?. Curr Opin Endocrinol Diabetes 9 (2002) 444-450
2. Moghetti P., Tosi F., Tosti A., Negri C., Misciali C., Perrone F., et al. Comparison of spironolactone, flutamide and finasteride efficacy in the treatment of hirsutism. a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 85 (2000) 89-94
3. Kelestimur F., Everest H., Unluhizarci K., Bayram F., and Sahin Y. A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism. Eur J Endocrinol 150 (2004) 351-354
4. Moghetti P., Tosi F., Castello R., Magnani C.M., Negri C., Brun E., et al. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment. evidence that androgens impair insulin action in women. J Clin Endocrinol Metab 81 (1996) 952-960
5. De Leo V., Lanzetta D., D'Antona D., la Marca A., and Morgante G. Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 83 (1998) 99-102
6. DiamantiKandarakis E., Mitrakou A., Raptis S., Tolis G., and Duleba A.J. The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J Clin Endocrinol Metab 83 (1998) 2699-2705
7. Gambineri A., Pelusi C., Genghini S., Morselli-Labate A.M., Cacciari M., Pagotto U., et al. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol 60 (2004) 241-249
8. Ibanez L., Valls C., Cabre S., and De Zegher F. Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism. the key role of early, low-dose flutamide. J Clin Endocrinol Metab 89 (2004) 4716-4720